BDSX

Biodesix Inc.

NasdaqAdd to watchlist

Healthcare · Diagnostics & Research

$29.20

+$0.39+1.35%

Delayed · 2026-09-18T20:00:00.000Z · marketstack

20 open-market sales on file ($118K), none of them under a pre-arranged plan. Who, and when

Aug 24, 2026$29.20

+$3.81+15.01%over 1M

Session

Day range52% of range

$28.39$29.96

Fundamentals

Visualize fundamentals and more

Market cap: 300.64M
P/E ratio: -

Revenue grew +24.08% in FY2025, +15.22% faster than its sector. The median across Healthcare companies this platform tracks is +8.87%.

Risk factors, year on year

Item 1AFeb 2026 10-KMar 2025

added: 57
dropped: 59
re-drafted: 30

Out of 294 passages in this year’s Item 1A.

New this year

Enhanced U.S. tariffs, import/export restrictions or other trade barriers may have a negative effect on global economic conditions, financial markets and our business.

115 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add

What it says it is exposed to

From Item 1A of its most recent 10-K, filed February 2026.

FDA approval
Reimbursement
Litigation
Product recalls
Data privacy
Debt covenants
Cybersecurity
Export controls

And 17 more.

FDA approval
In addition to reducing our revenue, the loss of one or more of these relationships may reduce our exposure to research and clinical trials that facilitate the collection and incorporation of new information into our biobank. We engage in conversations with …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Recent activity

Aug 12 SCHULER JACK W bought 15,000 shares Insider trading Form 4 about $367k
Aug 11 SCHULER JACK W bought 13,700 shares Insider trading Form 4 about $329k
Aug 5 Results announcement Company filing 8-K

15 more events are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Discussion

No comments yet

Set a username to join the discussion. It’s the only thing shown next to what you post, never your email address.

Comments are written by other users. Nothing here is investment advice and nothing is checked for accuracy.

Updated Sep 18, 2026 · the last close

Biodesix Inc. investor relations

What BDSX has filed with the SEC. This is not Biodesix Inc.’s own investor relations site: these filings are the primary source that site publishes from.

Companies like Biodesix Inc.

Also filed under Diagnostics & Research, ranked by how closely they sit beside BDSX.

TMOThermo Fisher Scientific Inc.compare with BDSX
ILMNILLUMINA, Inc.compare with BDSX
DHRDanaher Corp.

TWSTTwist Bioscience Corpcompare with BDSX

AAgilent TECHNOLOGIES, Inc.compare with BDSX

Ask about Biodesix Inc.

The assistant answers from what BDSX has actually filed: 7 annual reports filed with the SEC, 50 Form 4 filings from the last year and 1 fund that holds it. Every figure in a reply links to the filing it came from, so an answer can be checked rather than believed.

Press one and the answer appears right here on the page, from BDSX's filings and figures. One a day without an account; a free account has its own, and no card.

See how much of Biodesix Inc. each of these investors holds, and every quarter they moved.

Ten seconds. No card. Nothing to cancel.

No card, no broker connection.

Continue with Google

What an account lets you do with Biodesix Inc.

Be told the moment a BDSX insider trades
Put Biodesix Inc. on a watchlist for a free alert, the bell and a daily email, when a Form 4 worth a row is filed, with vesting and automatic tax sales already struck out so what lands is a decision, not paperwork.
The full filing historyMeasure
Ask what growth the price is already betting on
Biodesix Inc.'s income statement, balance sheet and cash flow as filed, and the ratios computed from them, plus a reverse DCF that holds today's price fixed and solves for the growth it requires.
The reverse DCFMeasure
Watch the same stakes the professionals are watching
Every tracked position priced at the quarter it was filed and diffed against the one before it: how big a bet each one is, and by how much it changed.
Every position, sizedMeasure
Interrogate the filing, not the internet
Ask anything about Biodesix Inc.'s fundamentals. The assistant answers from its own filings and cites the figure, never a guess from the open web.

Create a free account See what the paid plans add

Free, no card, and it does not expire.

Risk factors, year on year

Item 1AFeb 2026 10-KMar 2025

added: 57
dropped: 59
re-drafted: 30

Out of 294 passages in this year’s Item 1A.

New this year

Enhanced U.S. tariffs, import/export restrictions or other trade barriers may have a negative effect on global economic conditions, financial markets and our business.

115 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add

What it says it is exposed to

From Item 1A of its most recent 10-K, filed February 2026.

FDA approval
Reimbursement
Litigation
Product recalls
Data privacy
Debt covenants
Cybersecurity
Export controls

And 17 more.

FDA approval
In addition to reducing our revenue, the loss of one or more of these relationships may reduce our exposure to research and clinical trials that facilitate the collection and incorporation of new information into our biobank. We engage in conversations with …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Recent activity

Aug 12 SCHULER JACK W bought 15,000 shares Insider trading Form 4 about $367k
Aug 11 SCHULER JACK W bought 13,700 shares Insider trading Form 4 about $329k
Aug 5 Results announcement Company filing 8-K

15 more events are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add